Aquestive Therapeutics (AQST) Cut to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a research report sent to investors on Wednesday.

According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. “

A number of other research analysts also recently weighed in on the company. Wedbush set a $34.00 price target on Aquestive Therapeutics and gave the company a buy rating in a report on Thursday, October 25th. BMO Capital Markets initiated coverage on Aquestive Therapeutics in a report on Monday, August 20th. They set an outperform rating on the stock. Royal Bank of Canada initiated coverage on Aquestive Therapeutics in a report on Monday, August 20th. They set an outperform rating and a $23.00 price target on the stock. Finally, JMP Securities initiated coverage on Aquestive Therapeutics in a report on Monday, August 20th. They set an outperform rating and a $29.00 price target on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $29.00.

Shares of Aquestive Therapeutics stock opened at $8.59 on Wednesday. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.63 and a quick ratio of 3.42. Aquestive Therapeutics has a 12-month low of $7.90 and a 12-month high of $20.70.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.15). The firm had revenue of $13.27 million during the quarter, compared to analyst estimates of $14.75 million. As a group, equities research analysts expect that Aquestive Therapeutics will post -1 earnings per share for the current fiscal year.

In other Aquestive Therapeutics news, CFO John T. Maxwell purchased 10,000 shares of the stock in a transaction dated Wednesday, November 21st. The shares were acquired at an average price of $9.80 per share, for a total transaction of $98,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Keith J. Kendall purchased 7,950 shares of the stock in a transaction dated Friday, November 23rd. The shares were acquired at an average price of $10.10 per share, for a total transaction of $80,295.00. The disclosure for this purchase can be found here. Insiders have bought 20,650 shares of company stock worth $205,581 in the last quarter.

Several hedge funds have recently modified their holdings of AQST. Massachusetts Financial Services Co. MA acquired a new stake in Aquestive Therapeutics in the 3rd quarter valued at $5,305,000. Engineers Gate Manager LP acquired a new stake in Aquestive Therapeutics in the 3rd quarter valued at $464,000. Wasatch Advisors Inc. acquired a new stake in Aquestive Therapeutics in the 3rd quarter valued at $2,545,000. Keybank National Association OH acquired a new stake in Aquestive Therapeutics in the 3rd quarter valued at $239,000. Finally, Alliancebernstein L.P. acquired a new stake in Aquestive Therapeutics in the 3rd quarter valued at $14,323,000. Institutional investors and hedge funds own 8.46% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Read More: What is a Futures Contract?

Get a free copy of the Zacks research report on Aquestive Therapeutics (AQST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit